Skip to main content
SpringerLink
Log in

Treatment of hepatocellular carcinoma by means of radiopharmaceuticals

  • Review Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Several techniques have been developed for radionuclide therapy of hepatocellular carcinoma (HCC). Medical literature databases (Pubmed, Medline) were screened for available literature and articles were critically analysed as to their scientific relevance. In a palliative setting, intra-arterial administration of 131I-Lipiodol yields responses in 17–92% of patients. According to a randomised study, 131I-Lipiodol was far better tolerated than classic chemo-embolisation. The additive value of a single 131I-Lipiodol administration following partial liver resection for HCC was evaluated and evidence is available that adjuvant radionuclide treatment reduces the recurrence rate. Data concerning the role of 131I-Lipiodol in bridging patient to liver transplantation are scarce but suggest a potential benefit in terms of reducing the drop-out rate while patients are listed for transplantation. 188Re- and 90Y-labelled conjugates are emerging and initial clinical data are promising. Treatment of HCC with 90Y-labelled microspheres is likely as efficacious as treatment with radiolabelled Lipiodol but pretreatment 99mTc-MAA scintigraphy is required in order to exclude patients with significant lung shunting. Several antibodies targeting antigens expressed on HCC have been radiolabelled, almost exclusively with 131I, and evaluated in a preclinical or clinical setting. The use of radiolabelled Lipiodol and microspheres allows for selective targeting of HCC with limited toxicity. Prospective, randomised controlled trials demonstrating that both treatment modalities may provide a survival benefit in a palliative setting are mandatory. In addition, future research should focus on the complementary role of radionuclide treatment in patients at risk for recurrent disease following partial liver resection or while awaiting liver transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Röcken C, Carll-McGrath S. Pathology and pathogenesis of hepatocellular carcinoma. Dig Dis 2001;19:269–78

    Google Scholar 

  2. Parkin MD, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: globocan 2000. Int J Cancer 2001;94:153–6

    Google Scholar 

  3. Monto A, Wright TL. The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol 2001;28:441–9

    Google Scholar 

  4. Sherman M. Surveillance for hepatocellular carcinoma. Semin Oncol 2001;28:450–9

    Google Scholar 

  5. Coackley FV, Schwartz LH. Imaging of hepatocellular carcinima: a practical approach. Semin Oncol 2001;28:460–73

    Google Scholar 

  6. Ward J, Robinson PJ. How to detect hepatocellular carcinoma in cirrhosis. Eur Radiol 2002;12:2258–72

    Google Scholar 

  7. Caturelli E, Ghittoni G, Roselli P, De Palo M, Anti M. Fine needle biopsy of focal liver lesions: the hepatologist’s point of view. Liver Transplant 2004;10:S26–9

    Google Scholar 

  8. Llovet JM, Fuster J, Bruix J, Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplant 2004;10:S115–20

    Google Scholar 

  9. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Eng J Med 1996;334:693–699

    Google Scholar 

  10. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429–42

    Google Scholar 

  11. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907–17

    Google Scholar 

  12. Dusheiko GM, Hobbs KE, Dick R, Burroughs AK. Treatment of small hepatocellular carcinomas. Lancet 1992;340:285–8

    Google Scholar 

  13. Castells A, Bruix J, Bru C, et al. Treatment of hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993;18:1121–6

    Google Scholar 

  14. Livraghi T, Bolondi L, Buscarini L, et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. J Hepatol 1995;22:522–6

    Google Scholar 

  15. Yamamoto J, Okada S, Shimada K, et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001;34:707–13

    Google Scholar 

  16. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolisation for unresectable hepatocellular carcinoma: meta-analysis of randomised controlled trials. Radiology 2002;224:47–54

    Google Scholar 

  17. Reidy DL, Schwartz JD. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials—I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma. Anticancer Drugs 2004;15:427–37

    Google Scholar 

  18. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002;3:593–603

    Google Scholar 

  19. Lin DY, Lin SM, Liaw YF. Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12:S319–28

    Google Scholar 

  20. Treiber G. Systemic treatment of hepatocellular carcinoma. Dig Dis 2001;19:311–23

    Google Scholar 

  21. Aguayo A, Patt YZ. Nonsurgical treatment of hepatocellular carcinoma. Semin Oncol 2001;28:503–13

    Google Scholar 

  22. Leung TW, Johnson PJ. Systemic therapy for hepatocellular carinoma. Semin Oncol 2001;28:514–20

    Google Scholar 

  23. Mathurin P, Rixe O, Bernards B, et al. Review article: overview of medical treatments in unresectable hepatocellular carcinoma—an impossible meta-analysis? Aliment Pharmacol Ther 1998;12:111–26

    Google Scholar 

  24. Schwartz JD, Beutler AS. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials—II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anticancer Drugs 2004;15:439–52

    Google Scholar 

  25. Cheng JC, Chuang VP, Cheng SH, et al. Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemo-embolisation. Int J Cancer 2001;96:243–52

    Google Scholar 

  26. Cheng JC, Wud JK, Huanga CM, et al. Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. Radiother Oncol 2002;63:41–5

    Google Scholar 

  27. Cheng SH, Lin YM, Chuang VP, et al. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 1999;14:1025–33

    Google Scholar 

  28. Seong J, Park HS, Han KH, et al. Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with arterial chemoembolization. Int J Radiat Oncol Biol Phys 2000;47:1331–5

    Google Scholar 

  29. Nakakuma K, Tashiro S, Hiraoka T, Ogata K, Ootsuka K. Hepatocellular carcinoma and metastatic cancer detected by iodized oil. Radiology 1985;154:15–7

    Google Scholar 

  30. Bhattacharya S, Dhillon AP, Winslet MC, et al. Human liver cells and endothelial cells incorporate iodised oil. Br J Cancer 1996;73:877–81

    Google Scholar 

  31. Al-Mufti RA, Pedley RB, Marshall D, et al. In vitro assessment of Lipiodol-targeted radiotherapy for liver and colorectal cancer cell lines. Br J Cancer 1999;79:1665–71

    Google Scholar 

  32. Ho S, Lau WY, Leung TWT, Johnson PJ. Internal radiation therapy for patients with primary or metastatic hepatic cancer. Cancer 1998;83:1894–907

    Google Scholar 

  33. Risse JH, Grünwald F, Kersjes W, et al. Intraarterial HCC therapy with I-131-Lipiodol. Cancer Biother Radiopharm 2000;15:65–70

    Google Scholar 

  34. Rindani R, Hugh T, Roche J, Roach PJ, Smith RC. 131I Lipiodol therapy for unresectable hepatocellular carcinoma. Aust NZ J Surg 2002;72:210–4

    Google Scholar 

  35. Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemoembolization versus intraarterial injection of 131I-labeled iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997;26:1156–61

    Google Scholar 

  36. Bhattacharya S, Novell JR, Dusheiko GM, Hilson AJ, Dick R, Hobbs KE. Epirubicin-Lipiodol chemotherapy versus 131iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 1995;76:2202–10

    Google Scholar 

  37. Raoul JL, Guyader D, Bretagne JF, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994;35:1782–7

    Google Scholar 

  38. Brans B, Van Laere K, Gemmel F, et al. Combining iodine-131 Lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2002;29:928–32

    Google Scholar 

  39. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145–51

    Google Scholar 

  40. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial Lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomized trial. Lancet 1999,353:797–801

    Google Scholar 

  41. Pocock S, White I. Trials stopped too early: too good to be true? Lancet 1999;353:943–4

    Google Scholar 

  42. Partensky C, Sassolas G, Henry L, Paliard P, Maddern G. Intra-arterial iodine 131-labeled Lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma. A phase 2 clinical study. Arch Surg 2000;135:1298–300

    Google Scholar 

  43. Raoul JL, Messner M, Boucher E, Bretagne JF, Campion JP, Boudjema K. Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of I131-labelled Lipiodol. Br J Surg 2003;90:1379–83

    Google Scholar 

  44. Boucher E, Corbinais S, Rolland Y, et al. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 2003;38:1237–41

    Google Scholar 

  45. Brans B, De Winter F, Defreyne L, et al. The anti-tumoural activity of neoadjuvant intra-arterial 131I-Lipiodol treatment for hepatocellular carcinoma: a pilot study. Cancer Biother Radiopharm 2001;16:333–8

    Google Scholar 

  46. Wall WJ, Marotta PJ. Surgery and transplantation for hepatocellular cancer. Liver Transplant 2000;6:S16–22

    Google Scholar 

  47. Monsieurs M, Bacher K, Brans B, et al. Patient dosimetry for 131-I-Lipiodol therapy. Eur J Nucl Med Mol Imaging 2003;30:554–61

    Google Scholar 

  48. Garin E, Laffont S, Rolland Y, et al. Safe radiation exposure of medical personnel by using simple methods of radioprotection while administering 131I-Lipiodol therapy for hepatocellular carcinoma. Nucl Med Commun 2003;24:671–8

    Google Scholar 

  49. Wang SJ, Lin WY, Chen MN, Shen LH, Tsai ZT, Ting G. Preparation and biodistribution of yttrium-90 Lipiodol in rats following hepatic arterial injection. Eur J Nucl Med 1995;22:233–6

    Google Scholar 

  50. Wang SJ, Lin WY, Lui WY, Chen MN, Tsai ZT, Ting G. Hepatic artery injection of yttrium-90-Lipiodol: biodistribution in rats with hepatoma. J Nucl Med 1996;37:332–5

    Google Scholar 

  51. Yu J, Häfeli UO, Sands M, Dong Y. 90Y-oxine-ethiodol, a potential radiopharmaceutical for the treatment of liver cancer. Appl Radiat Isotopes 2003;58:567–73

    Google Scholar 

  52. Wang SJ, Lin WY, Chen MN, et al. Radiolabelling of Lipiodol with generator-produced 188Re for hepatic tumour therapy. Appl Radiat Isotopes 1996;47:267–71

    Google Scholar 

  53. Wang SJ, Lin WY, Chen MN, et al. Biodistribution of rhenium-188 Lipiodol infused via the hepatic artery of rats with hepatic tumours. Eur J Nucl Med 1996;23:13–7

    Google Scholar 

  54. Jeong JM, Kim YJ, Lee YS, et al. Lipiodol solution of a lipophilic agent, 188Re-TDD, for the treatment of liver cancer. Nucl Med Biol 2001;28:197–204

    Google Scholar 

  55. Lee YS, Jeong JM, Kim YJ, et al. Synthesis of 188Re-labelled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl Med Commun 2002;23:237–42

    Google Scholar 

  56. Sundram FX, Jeong J-M, Zanzonico P, et al. Trans-arterial rhenium-188 Lipiodol in the treatment of inoperable hepatocellular carcinoma. An IAEA sponsored multi-centre phase 1 study. World J Nucl Med 2002;1:5–11

    Google Scholar 

  57. Sundram F, Chau TC, Onkhuudai P, Bernal P, Padhy AK. Preliminary results of transarterial rhenium-188 HDD Lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2004;31:250–7

    Google Scholar 

  58. Lambert B, Bacher K, Defreyne L, et al. 188Re-HDD/Lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med 2005;46:60–6

    Google Scholar 

  59. Garin E, Noiret N, Malbert C, et al. Development and biodistribution of 188Re-SSS Lipiodol following injection into the hepatic artery of healthy pigs. Eur J of Nucl Med Mol Imaging 2004;31:542–6

    Google Scholar 

  60. Boschi A, Uccelli L, Duatti A, et al. A kit formulation for the preparation of 188Re-Lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma. Nucl Med Commun 2004;25:691–9

    Google Scholar 

  61. Houle S, Yip TK, Shepherd FA, et al. Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. Radiology 1989;172:857–60

    Google Scholar 

  62. Shepherd FA, Rotstein LE, Houle S, Yip TC, Paul K, Sniderman KW. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 1992;70:2250–4

    Google Scholar 

  63. Carr BI. Hepatic arterial 90ytrrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transplant 2004;10:S107–10

    Google Scholar 

  64. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004;127:S194–205

    Google Scholar 

  65. Lau WY, Leung WT, Ho S, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994;70:994–9

    Google Scholar 

  66. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol 2005;16:195–203

    Google Scholar 

  67. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005;16:205–13

    Google Scholar 

  68. Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997;24:293–8

    Google Scholar 

  69. Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90 yttrium-microspheres for inoperable hepatic tumours. Int J Radiat Oncol Biol Phys 1995;33:919–24

    Google Scholar 

  70. Salem R, Lewandowski R, Roberts C, et al. Use of yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004;15:335–45

    Google Scholar 

  71. Liu L, Jiang Z, Teng GJ, et al. Clinical and experimental study on regional administration of phosphorus 32 microspheres in treating hepatic carcinoma. World J Gastroenterol 1999;5:492–505

    Google Scholar 

  72. Häfeli UO, Casillas S, Dietz DW, et al. Hepatic tumour radioembolization in a rat model using radioactive rhenium (Re-186/Re-188) glass microspheres. Int J Radiat Oncol Biol Phys 1999;44:189–99

    Google Scholar 

  73. Häfeli UO, Roberts WK, Pauer GJ, Kraeft ST, Macklis RM. Stability of biodegradable radioactive rhenium (Re-186 and Re-188) microspheres after neutron-activation. Appl Radiat Isotopes 2001;54:869–79

    Google Scholar 

  74. Mumper RJ, Ryo UY, Jay M. Neutron-activated holmium-166-poly (L-lactic acid) microspheres: a potential agent for the internal radiation therapy of hepatic tumours. J Nucl Med 1991;32:2139–43

    Google Scholar 

  75. Nijsen F, Rook D, Brandt C, et al. Targeting of liver tumour in rats by selective delivery of holmium-166 loaded microspheres: a biodistribution study. Eur J Nucl Med 2001;28:743–49

    Google Scholar 

  76. Zeng ZC, Tang ZY, Xie H, et al. Radioimmunotherapy for unresectable hepatocellular carcinoma using 131I-Hepama-1 mAb: preliminary results. J Cancer Res Clin Oncol 1993;119:257–9

    Google Scholar 

  77. Zeng ZC, Tang ZY, Liu KD, Lu JZ, Xie H, Yao Z. Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131I-anti-HCC mAb. Phase I/II clinical trials. J Cancer Res Clin Oncol 1998;124:275–80

    Google Scholar 

  78. Zeng ZC, Tang ZY, Yang BH, et al. Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2002;29:1657–68

    Google Scholar 

  79. Order S, Pajak T, Leibel S, et al. A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study. Int J Radiat Oncol Biol Phys 1991;20:953–63

    Google Scholar 

  80. Liu KD, Tang ZY, Bao YM, et al. Radioimmunotherapy for hepatocellular carcinoma (HCC) using 131I-anti HCC isoferritin IgG: preliminary results of experimental and clinical studies. Int J Radiat Oncol Biol Phys 1989;16:319–23

    Google Scholar 

  81. Uraki J, Yamakado K, Nakatsuka A, Takeda K. Transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma invading the portal veins: therapeutic effects and prognostic factors. Eur J Radiol 2004;51:12–8

    Google Scholar 

  82. Ho S, Lau JW, Leung TW. Intrahepatic 90Y-microspheres for hepatocellular carcinoma. J Nucl Med 2001;42:1587–9

    Google Scholar 

  83. Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 1998;40:583–92

    Google Scholar 

  84. Van de Wiele C, Revets H, Mertens N. Radioimmunoimaging. Advances and prospects. Q J Nucl Med Mol Imaging 2004;48:317–25

    Google Scholar 

  85. Roselli M, Greiner JW, Nieroda CA, Guzdagni F. New biological strategies to improve radioimmunodetection/therapy effectiveness. In: Riva P, editor. Cancer radioimmunotherapy. Harwood Academic Publishers; 1999. pp. 103–22

Download references

Acknowledgements

Bieke Lambert is funded by the ‘Bijzonderonderzoeks Fonds (Ghent University, No 011D9501)’ and Christophe Van de Wiele by the ‘Nationaal Fonds voor Wetenschappelijk Onderzoek’.

Author information

Authors and Affiliations

  1. Nuclear Medicine Division, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium

    Bieke Lambert & Christophe Van de Wiele

Authors
  1. Bieke Lambert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christophe Van de Wiele
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christophe Van de Wiele.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lambert, B., Van de Wiele, C. Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. Eur J Nucl Med Mol Imaging 32, 980–989 (2005). https://doi.org/10.1007/s00259-005-1859-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-005-1859-z

Keywords

Search

Navigation